NCT02820025

Brief Summary

The current study is designed to investigate the difference of plasma orexin A levels between doxapram group and controlled group at emergence time from sevoflurane-remifentanil anesthesia who will undergo elective lumbar surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2015

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 25, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 30, 2016

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

January 18, 2017

Status Verified

January 1, 2017

Enrollment Period

1.5 years

First QC Date

May 25, 2016

Last Update Submit

January 17, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • orexin A concentrations

    1 year

Study Arms (2)

doxapram group

EXPERIMENTAL

the doxapram group iv doxapram 1mg/kg,

Drug: doxapram

Controlled group

PLACEBO COMPARATOR

the controlled group given equal volume of saline with the doxapram group.

Other: saline

Interventions

doxapram group
salineOTHER
Controlled group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participant is Adult (≥18 years old and ≤75 years old)
  • Participants with a Body Mass Index (BMI) 20-25 kg/m2
  • Participants with ASA physical status Ⅰor Ⅱ
  • Participants with Heart function rating Ⅰor Ⅱ
  • patients will undergo elective lumbar surgery and general anesthesia
  • The operation time is 2h to 4h.

You may not qualify if:

  • Participant is a pregnant woman or a nursing mother.
  • Participants have a history of narcotics allergic reactions.
  • indices of liver or kidney function is twice higher than normal.
  • Participants have a history or diagnosis of depression.
  • Participants have a history of Brain Trauma.
  • Participants have a history of narcotics addiction or drug addiction.
  • Participants or his family have an International Classification of Sleep Disorders diagnosis of obstructive sleep apnea syndrome.
  • patients are refuse this trail or are not able to sign informed consent. -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anesthesiology department of General Hospital of Ningxia Medical University

Yinchuan, Ningxia, 750004, China

Location

MeSH Terms

Interventions

DoxapramSodium Chloride

Intervention Hierarchy (Ancestors)

PyrrolidinonesPyrrolidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Zhihua Wang, M.D.

    General Hospital of Ningxia Medical University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2016

First Posted

June 30, 2016

Study Start

October 1, 2015

Primary Completion

April 1, 2017

Study Completion

December 1, 2017

Last Updated

January 18, 2017

Record last verified: 2017-01

Locations